Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029

Wyeth is now a wholly owned subsidiary of Pfizer72 enrolled

Overview

This is a multiple dose study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of an investigational new drug.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

DOUBLE

Enrollment

Conditions

Healthy

Interventions

MYO-029DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Men aged 18 to 45 years inclusive on study day 1. * Elderly men and women aged 65 to 80 years inclusive on study day 1. * Women must be postmenopausal for \> or = 1 year (with estradiol \< 25 pg/mL and an FSH \> 40 mIU/mL). * Healthy as determined by the investigator on the basis of medical history, physical examination, vital signs, clinical laboratory test results, and 12-leave electrocardiogram. * Elderly subjects may have stable, nonclinically significant abnormalities on physical examination, and laboratory evaluation. * Non-smoker.

Outcomes

Primary Outcomes

To assess safety and tolerability.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.